International Experts Discuss OptiTROP-Lung06: ADC Plus Immunotherapy Challenges the First-Line Standard in PD-L1-Negative NSCLC
The 2026 Congress of the European Society for Medical Oncology (ESMO) was held in Madrid, Spain, from October 23 to 27. At this premier global oncology event, the OptiTROP-Lung06 study, led by Professor Caicun Zhou of Shanghai East Hospital, presented its findings in a major oral presentation, with simultaneous publication in the New England Journal of Medicine (NEJM). This Phase III study provided the first head-to-head evidence that the TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) plus pembrolizumab was superior to the standard regimen of platinum-based doublet chemotherapy plus pembrolizumab as first-line treatment for patients with driver gene-negative, PD-L1-negative (expression <1%) nonsquamous non-small cell lung cancer (NSCLC).









